Skip to main content
. Author manuscript; available in PMC: 2009 Dec 1.
Published in final edited form as: Neuropsychopharmacology. 2009 Jan 21;34(7):1733–1742. doi: 10.1038/npp.2008.230

Figure 6.

Figure 6

PKCε-/- mice show enhanced tolerance to WIN55,212-2-induced hypothermia and analgesia following equipotent, twice daily injections of WIN55,212-2 for 6 days. (a) PKCε-/- mice showed tolerance to WIN55,212-2 induced hypothermia (*p< 0.001 by Bonferroni post-hoc test). (b) PKCε+/+ mice also showed tolerance to WIN55,212-2-induced hypothermia (*p< 0.001 by Bonferroni post-hoc test). (c) The magnitude of tolerance to WIN55,212-2-induced hypothermia was greater in PKCε-/- compared with PKCε+/+ mice. (d) PKCε-/- mice showed tolerance to WIN55,212-2-induced analgesia (*p<0.05 by Bonferroni post-hoc test). (e) PKCε+/+ mice did not show significant tolerance to WIN55,212-2-induced analgesia. (f) The magnitude of chronic tolerance to WIN55,212-2 induced analgesia was greater in PKCε-/- compared with PKCε+/+ mice (*p< 0.05 by Bonferroni post-hoc test). Data represent mean ± standard error of 5 to 9 mice per genotype.